Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Journal of Colorado.
Press releases published on April 28, 2025
80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting
GlobeNewswire
·
April 28, 2025
80% of EVX-01 vaccine targets triggered a tumor-specific immune response, a substantially higher frequency than what has been reported for other similar vaccine candidates The data underscores the precision of Evaxion’s AI-Immunology™ platform in selecting …
Radiopharm Theranostics Doses First Patient with 18F-RAD101 in U.S. Phase 2b Imaging Study of Brain Metastasis
GlobeNewswire
·
April 28, 2025
Phase 2b study evaluating diagnostic performance of 18F-RAD101 for suspected recurrent brain metastases from solid tumors of different origins Underscores Radiopharm’s commitment to developing transformative oncology radiopharmaceuticals SYDNEY, April 28, …
ImPact Biotech Presents Updated Efficacy Data from Evaluation of Padeliporfin VTP in LG UTUC and Intermediate-Risk Prostate Cancer at AUA 2025
GlobeNewswire
·
April 28, 2025
– Complete response (CR) observed in 79% (26/33) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase (ITP) of the ENLIGHTED Phase 3 trial evaluating Padeliporfin VTP in UTUC – – Padeliporfin …
Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire
·
April 28, 2025
CTX-471 monotherapy demonstrated efficacy in multiple murine models, including models highly resistant to immune checkpoint inhibitors. Combining CTX-471 with tovecimig (CTX-009) markedly increased anti-tumor efficacy in these models. Tovecimig in …
Pacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the Knee
GlobeNewswire
·
April 28, 2025
-- PCRX-201 demonstrated two years of clinically meaningful improvements in pain, stiffness and function across all structural severity subgroups, including advanced disease -- -- Study Findings Presented at 2025 OARSI World Congress-- BRISBANE, Calif., …
Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025
GlobeNewswire
·
April 28, 2025
DURHAM, N.C., April 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2025 …
Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC
GlobeNewswire
·
April 28, 2025
Phase 2 registration-intent trial enrolling Part 2a dose confirmation arms Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE …
BigCommerce and Silk Commerce Launch Distributed Ecommerce Hub to Power Scalable Storefront Networks for Dealers, Distributors and Franchises
GlobeNewswire
·
April 28, 2025
AUSTIN, Texas, April 28, 2025 (GLOBE NEWSWIRE) -- BigCommerce (Nasdaq: BIGC), an open SaaS, composable ecommerce platform for fast-growing and established B2C and B2B brands and retailers, today announced the launch of Distributed Ecommerce Hub, a new …
Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study
GlobeNewswire
·
April 28, 2025
VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant …
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
GlobeNewswire
·
April 28, 2025
Presentations at WHS and SAWC to highlight EscharEx’s mechanism of action, preclinical advantages over SANTYL®, and new data in treating VLUs and DFUs Findings reinforce the ongoing Phase III study in VLUs and support the planned DFU trial strategy YAVNE, …
Quanta Therapeutics Presents Late-Breaking Data for QTX3544, an Oral G12V-Preferring Multi-KRAS Inhibitor, at AACR Annual Meeting 2025
GlobeNewswire
·
April 28, 2025
- Preclinical data demonstrates synergy of QTX3544 with EGFR inhibitors, broadly enhancing anti-tumor activity - - Data supports ongoing Phase 1 clinical trial for QTX3544 as monotherapy and in combination with cetuximab in patients with KRASG12V mutations …
Calidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy Platform at AACR Annual Meeting
GlobeNewswire
·
April 28, 2025
SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the selection of IL15 …
IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025
GlobeNewswire
·
April 28, 2025
First gamma-delta (γδ) TCE to demonstrate significant γδ T cell expansion and activation, potentially offering an alternative to conventional CD3-based approaches without significant adverse events such as cytokine release syndrome (CRS) INB-600 TCE …
Adagene Appoints John Maraganore, Ph.D. as Executive Advisor
GlobeNewswire
·
April 28, 2025
- Biotech luminary to mentor C-suite and provide strategic guidance - SAN DIEGO and SUZHOU, China, April 28, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, …
Impulse Dynamics®’ INTEGRA-D Trial Completes Efficacy Phase
GlobeNewswire
·
April 28, 2025
Marlton, NJ, April 28, 2025 (GLOBE NEWSWIRE) -- Impulse Dynamics® plc, a global medical device company dedicated to improving the lives of people with heart failure (HF), is proud to announce that it reached an important milestone in the INTEGRA-D™ …
Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases
GlobeNewswire
·
April 28, 2025
New Analyses of PSC Data from Phase 2 SPRING Trial Show that Treatment with Nebokitug Is Associated with Dose-Dependent and Significant Improvements in Multiple Inflammatory and Fibrotic Biomarkers Further Confirms the Clinical Potential of Nebokitug As a …
CareCloud Launches Healthcare AI Center Set to Become World’s Largest with 500 AI Professionals
GlobeNewswire
·
April 28, 2025
SOMERSET, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDO), a leading provider of healthcare technology and generative AI solutions, today announced the official launch of its AI Center of Excellence (the “AI CoE”) — a major …
MicroAlgo Announces Strong Net Income and Cash Growth in 2024, Driven by Robust Demand for Central Processing Algorithm Services
GlobeNewswire
·
April 28, 2025
Shenzhen, April 28, 2025 (GLOBE NEWSWIRE) -- Shenzhen, China, April 28, 2025 – MicroAlgo Inc. (NASDAQ: MLGO), (the “Company”), a leading developer and application provider of bespoke central processing algorithms, today announced its financial results for …
LayerX Security Extends Series A Funding to $37M to Power Next-Gen Enterprise Browser Security, Challenges SSE Solutions and Enterprise Browsers
GlobeNewswire
·
April 28, 2025
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- LayerX, the leading Secure Enterprise Browser Extension, today announced it has raised an $11 million extension to its $26 million Series A funding round, bringing the total amount raised to $45 million. The …
Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.
GlobeNewswire
·
April 28, 2025
Acquisition of approximately 71% stake in Kokomodo Ltd. Acquisition uniquely combines Pluri's mass-scale cell production expertise with Kokomodo Ltd.’s ability to craft real, controlled, climate-resilient cacao using cellular agriculture technology HAIFA, …